YB Urban Renewal Residential Development Ltd, formerly known as Cannassure Therapeutics Ltd, is an Israel-based urban renewal company. The Company is engaged mainly in urban renewal projects. In the urban renewal projects sector, the Company partakes in activities that aim to clear out areas of inner cities deemed to be neglected, unused and loosely maintained, in favor of new multifamily housing, business areas, as well as other developments improving the city landscape. The Firm aims to achieve economic, cultural and environmental renewal of the neglected inner city areas. The Company cooperates with a range of specialists in the field of urban renewal with knowledge and experience in urban planning and construction work.

Employees

Sector

Real Estate Development & Operations

More about the company

Market Cap	32.77M 11.23M 9.7M 8.94M 8.36M 15.68M 1.07B 15.92M 106M 41.14M 519M 42.14M 41.24M 1.8B	P/E Ratio 2024	-4.93x	P/E Ratio 2025	-9.22x
Enterprise Value	32.88M 11.27M 9.73M 8.97M 8.39M 15.73M 1.07B 15.98M 106M 41.29M 521M 42.29M 41.39M 1.8B	EV / Sales 2024	376x	EV / Sales 2025	-
Free-Float	54.11%	Yield 2024 *	-	Yield 2025	-

05-03	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-02	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
11-12	Y.B Urban Renewal - Residential Development Ltd announced that it expects to receive ILS 0.53001 million in funding	CI
25-09-10	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
24-09-01	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-07-11	Cannassure Therapeutics Ltd will Change its Name to Y.B URBAN RENEWAL - RESIDENTIAL DEVELOPMENT LTD	CI
24-03-27	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-03-26	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
23-08-31	Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-03-26	Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	CI
21-08-09	Cannassure Was Granted A Patent for an Oral Delivery Method of Cannabis and Cannabinoids Compositions by the Israel Patents Authority	CI

21-02-26	DanCann Pharma A/S : publishes Year-end report for 2020	AQ
21-01-18	Cannassure Therapeutics : DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology	AQ
21-01-18	Lipidor : and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO technology	AQ
20-12-15	DanCann Pharma A/S : enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland)	AQ
20-11-19	Lipidor : publishes interim report for Q3 2020	AQ

Manager	Title	Age	Since
Ada Bar Kama CEO	Chief Executive Officer	56	2022-03-30
Oren Attiya DFI	Director of Finance/CFO	44	-
Daniel Spira AUD	Comptroller/Controller/Auditor	71	2019-06-25

Director	Title	Age	Since
Nir Peles CHM	Chairman	53	2021-12-08
Shimon Bar-Kama BRD	Director/Board Member	73	2018-12-03
Varda Kalal BRD	Director/Board Member	58	2022-02-13

Cannassure Therapeutics Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

CSURE

IL0001110134

Real Estate Development & Operations

Valuation: Cannassure Therapeutics Ltd

Latest news : Cannassure Therapeutics Ltd

Press Releases: Cannassure Therapeutics Ltd

Quotes and Performance

Managers and Directors: Cannassure Therapeutics Ltd

Other Real Estate Development & Operations

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CANNASSURE THERAPEUTICS LTD	-7.54%	-22.20%	-	-	11.06M
NFINITI INC.	+252.94%	-99.80%	-99.74%	-	95.45B
SUN HUNG KAI PROPERTIES LIMITED	+1.56%	-5.42%	+36.92%	+13.92%	42.6B
CHINA RESOURCES LAND LIMITED	+1.08%	+3.61%	+37.82%	+15.42%	33.56B
MITSUBISHI ESTATE CO., LTD.	+1.60%	+6.74%	+57.74%	+150.21%	31.05B
EMAAR PROPERTIES	+8.33%	+3.36%	-13.01%	+93.39%	25.99B
MITSUI FUDOSAN CO., LTD.	+1.30%	+6.17%	+15.66%	+65.16%	26.04B
CHINA OVERSEAS LAND & INVESTMENT LIMITED	+0.45%	-2.30%	+14.69%	-11.36%	21.81B
CK ASSET HOLDINGS LIMITED	+1.62%	-0.94%	+37.53%	+2.50%	20.34B
SUMITOMO REALTY & DEVELOPMENT CO., LTD.	+2.91%	+1.45%	+25.21%	+95.24%	19.96B
Average	+26.43%	-0.58%	+12.54%	+53.06%	35.2B
Weighted average by Cap.	+77.80%	-0.54%	-10.19%	+52.42%

	2024	2025
Net sales	76K 26.04K 22.49K 20.73K 19.4K 36.36K 2.48M 36.92K 245K 95.42K 1.2M 97.73K 95.65K 4.17M	-
Net income	-3.68M -1.26M -1.09M -1M -938K -1.76M -120M -1.79M -11.83M -4.61M -58.26M -4.73M -4.63M -202M	-3M -1.03M -887K -817K -765K -1.43M -97.58M -1.46M -9.65M -3.76M -47.49M -3.85M -3.77M -164M
Net Debt	980K 336K 290K 267K 250K 469K 31.92M 476K 3.16M 1.23M 15.54M 1.26M 1.23M 53.79M	115K 39.41K 34.03K 31.36K 29.36K 55.02K 3.75M 55.87K 370K 144K 1.82M 148K 145K 6.31M